Home CRISPR GSK Taps UC Berkeley’s CRISPR Expertise to Accelerate Drug Development

GSK Taps UC Berkeley’s CRISPR Expertise to Accelerate Drug Development

150
0
CRISPR Collaboration

GlaxoSmithKline (GSK) announced a five-year collaboration with UC Berkeley and UCSF to establish a laboratory where state-of-the-art CRISPR techniques will be used to explore how gene mutations cause disease. This collaboration will potentially yield new technologies using CRISPR that would rapidly accelerate the discovery of new medicines.

Jennifer Doudna, a co-inventor of CRISPR technology, and UC Berkeley professor of molecular and cell biology and of chemistry and a Howard Hughes Medical Institute Investigator; Jonathan Weissman, a UCSF pioneer of CRISPR screening technology and an HHMI investigator; and Hal Barron, Chief Scientific Officer of R&D at GSK are behind this new exciting initiative.  Follow the UC Berkeley news posting for more details.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.